Evidence map›Paper›PMID 23190060›Full record

ArticleExpert review of cardiovascular therapy2012

Chronic kidney disease and risk of mortality, cardiovascular events or end-stage renal disease in older patients with hypertension.

Giorgio Gentile, Matias Trillini

Abstract readComment
PubMed Publisher
In one paragraph

Article in Expert review of cardiovascular therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Giorgio GentileMario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Villa Camozzi, Ranica, Italy. giorgio.gentile@marionegri.it
Matias Trillini

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Older individuals with a diagnosis of chronic kidney disease are at higher risk of all-cause mortality, cardiovascular (CV) events and end-stage renal disease. In such patients, the glomerular filtration rate may be estimated with different formulas, including the Modification of Diet in Renal Disease and the Chronic Kidney Disease Epidemiology Collaboration equations. The recently published post-hoc analysis of the long-term CV and renal outcomes of the ALLHAT trial that enrolled older patients with hypertension and high CV risk, but very low risk of renal disease progression, clearly highlights the interpretative pitfalls associated with this approach. Until future studies better establish the boundaries of 'normal' glomerular filtration rate in older people, physicians should not underestimate the importance of proteinuria and accurate glomerular filtration rate measurement in choosing the most appropriate antihypertensive combination in daily clinical practice, particularly in patients at high risk of progression to end-stage renal disease.

Identifiers

PMID23190060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.